Global Advances in Health and Medicine (http://www.GAHMJ.com) is proud to announce that Integrative Medicine in America: How Integrative Medicine Is Being Practiced in Clinical Centers Across the United States has been published in the July 2012 issue of GAHMJ.Portland, OR (PRWEB) August 06, 2012 Sponsored by The Bravewell Collaborative (http://www.bravewell. ...
The rest is here:
Global Advances in Health and Medicine to Publish Bravewell Collaborative Mapping Study
Newswise BOSTON (August 3, 2012) Tufts University School of Medicine today celebrated the achievements of the 33 Massachusetts high school students who participated in the Schools 2012 Teachers and High School Student Program. The program is one of Tufts signature initiatives to encourage high school students with diverse backgrounds to explore their interest in medicine and biomedical sciences. Established in 1989, the Tufts program supports the careers of aspiring young doctors and scientists by engaging them in a range of clinical and research opportunities across the Tufts Health Sciences campus in Boston.
Tufts University is committed to nurturing scientific curiosity among young people of diverse backgrounds, particularly those from communities that are underrepresented in medicine and the health sciences," said Harris Berman, M.D., dean of Tufts University School of Medicine. "The extraordinary students who participated in our high school program this summer have contributed immeasurably to the Tufts community, and we are proud to offer high school students the opportunity to launch promising careers as health professionals.
Our summer program for high school students offers invaluable experience to young people who might not otherwise have opportunities to explore their budding interests in medicine and the biomedical sciences, said Joyce Sackey, M.D., dean for multicultural affairs and global health and associate professor at Tufts University School of Medicine. Tufts Teachers and High School Students Program is one of our key initiatives to support the educational development of youth in our community.
Selected high school students participated in a seven-week program and spent up to 25 hours each week in various positions at Tufts University School of Medicine, Tufts University School of Dental Medicine, Sackler Graduate School of Biomedical Sciences at Tufts or Tufts Medical Center. Students also took a gross anatomy course taught by Tufts medical students and gained knowledge of laboratory-based science; in the process, students developed relationships with medical and graduate student mentors that Tufts expects will continue beyond the summer program.
The Tufts program also includes an independent study, the findings of which the students presented to the Tufts community, family and friends today. Participating students were:
Edward Akubude (Mattapan), 16, Concord-Carlisle Regional High School Reduction of OCD symptoms in Mice Carlos Angeles (Norton), 19, Xaverian Brothers High School The Relationship between Diabetes and Diet Christina Augustin (Medford), 16, Prospect Hill Academy Charter School The Effects of Marijuana on Pregnancy Janika Beatty (Malden), 17, Community Charter School of Cambridge The Effects of Marijuana on Pregnancy Carrington Cazeau (Boston), 16, Natick High School Zebrafish fin Mutations Walter Chacon (Lynn), 16, Phillips Academy Andover The Relationship between Obesity and Depression Malka Forman (Brighton), 17, Maimonides School Lower limb ischemic threshold with near infrared spectrometry device John Frazer (Quincy), 16, Boston College High School Evidence Based Review of Domestic Violence (The reporting and recognition by healthcare providers of child abuse and neglect in the Latino population) Ericka Garcia (Brookline) 15, Brookline High School Leukemia in Children Bryant Gill (Foxboro), 17, Xaverian Brothers High School "Correlation of Neuronal Signal to Astrocyte Morphology" Nathan Gill (Foxboro), 16, Xaverian Brothers High School Reduction of OCD symptoms in Mice Yvonne Hamisi (Springfield), 18, Baystate-Springfield Educational Partnership Cardiac Differences between Athletes and Non-Athletes Elyane James (Dorchester), 18, Marblehead High School Evidence Based Review of Domestic Violence (The reporting and recognition by healthcare providers of child abuse and neglect in the Latino population) Hyunji Koo (North Andover), 16, Phillips Academy Andover Cross-cultural communication and the doctor-patient relationship Fatima Khan (Somerville), 16, Prospect Hill Academy Charter School Abdominal Aortic Aneurysms Ryan Kuehl (Springfield), 18, Baystate-Springfield Educational Partnership Too Much Exercise? Anthony Nino Lambert (Hanover), 16, Boston College High School Factors that affect the Concentration of Serine Jessica Mar (Brighton), 16, Boston Latin School Physician Wellness Abby Mendez (Roxbury), 17, City on a Hill Evidence Based Review of Domestic Violence (The reporting and recognition by healthcare providers of child abuse and neglect in the Latino population) Jasmine Ngan (Somerville), 16, Prospect Hill Academy Charter School The Effects of Storage Conditions on Bloodspot Amino Acids Blessing Ojini (Roxbury), 16, Needham High School The Benefits of Play in Child Development Emanuel Parrilla (Springfield), 18, Baystate-Springfield Educational Partnership The effects of a torn ACL in later life Klarissa Ramkissoon (Milton), 17, Milton High School Behavioral Testing in Mice Krystina San Soucie (Upton), 16, Nipmuc Regional High School Methods to Maximize Serine Levels Abdullahi Tahlil (Roxbury), 17, Match High School Child Health Assessment Mapping Project Lisa Tam (Boston), 18, John D. O'Bryant High School of Math and Science Effectiveness of Home Visits Compared with Standard Care Dorothy Tran (Boston), 17, The Winsor School Child Health Assessment Mapping Project Arianna Unger (Newton), 17, Maimonides School "A Comparative Study of Two Orthotic Systems Used for the Assisted Ambulation of a Child with Spina Bifida" Camille Van Allen (Milton), 17, Milton High School Benefits of Breast Feeding Winnie Wang (Boston), 18, Boston Latin School Relationship between Toxic/Nutritional and Leber's Hereditary Optic Neuropathy Natalie Wolanski (Springfield), 17, Baystate-Springfield Educational Partnership Concussions in Sports and Society Davonte Willis (Quincy), 18, Quincy High School Factors that affect the Concentration of Amine Acids Kavin Zhu (Boston), 17, Boston Latin School Genetic Disease as Exemplified by Hunter Syndrome
The Teachers and High School Students Program is one of a number of "pipeline" programs at Tufts University School of Medicine designed to engage diverse students interested in the fields of medicine and biomedical sciences. Tufts offers programs for diverse students in middle school, high school, and college, as well as college graduates.
About Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences at Tufts University are international leaders in innovative medical education and advanced research. The School of Medicine and the Sackler School are renowned for excellence in education in general medicine, biomedical sciences, special combined degree programs in business, health management, public health, bioengineering and international relations, as well as basic and clinical research at the cellular and molecular level. Ranked among the top in the nation, the School of Medicine is affiliated with six major teaching hospitals and more than 30 health care facilities. Tufts University School of Medicine and the Sackler School undertake research that is consistently rated among the highest in the nation for its effect on the advancement of medical science.
# # #
Read the rest here:
Tufts University School of Medicine Celebrates Program with Massachusetts Youth
Please check the URL for proper spelling and capitalization. If you're having trouble locating a destination on Yahoo!, try visiting the Yahoo! homepage or look through a list of Yahoo!'s online services.
Please try Yahoo Help Central if you need more assistance.
Excerpt from:
Sale of Viterra's Minority Interest in Medicine Hat nitrogen facility to CF Industries Holdings
Opponents of a greater government role in health care seem to overlook the system for military veterans, which has all the hallmarks of a socialized medicine program, an economist writes.
See original here:
HUNTINGTON BEACH, Calif., Aug. 3, 2012 (GLOBE NEWSWIRE) -- via PRWEB - Considered by many physicians of sexual medicine as the leading solution for premature ejaculation, Absorption Pharmaceuticals' Promescent will be featured at the SMSNA/ISSM conference in Chicago, August 26-30. Initially introduced at the SMSNA conference in Las Vegas in November 2011, Promescent continues to gain momentum in both the medical community and with men and women in the general public wishing to increase sexual satisfaction.
"Because of its effectiveness, we quickly established Promescent as the product of choice for PE by key opinion leaders of sexual medicine," says Jeff Abraham, Absorption's CEO. "We expect a lot of interest from a variety of physicians at the upcoming SMSNA/ISSM conference."
There are now over 200 physicians recommending Promescent to their patients who desire to extend their ejaculatory response time. Feedback from these patients and doctors has been overwhelmingly positive. The awareness of this premier PE treatment and its proprietary technology has been further highlighted with recent media coverage that has resulted in a significant consumer response for additional information and product samples. Absorption recently increased its sales team and is currently ramping up its FDA-compliant manufacturing capacity in order to meet product demand.
This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit http://www.prweb.com/releases/premature_ejaculation/sexual_medicine/prweb9764370.htm
Visit link:
Promescent® Featured in World Meeting on Sexual Medicine 2012
Opponents of a greater government role in health care seem to overlook the system for military veterans, which has all the hallmarks of a socialized medicine program.
See more here:
Today's Economist: Uwe E. Reinhardt: Would Americans Accept "Socialized Medicine"? Yes.
WALTHAM, Mass., Aug. 2, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (BGMD) today announced that its financial results for the second quarter of fiscal year 2012 will be released before market open on Thursday, August 9, 2012, followed the same day by a conference call and live webcast scheduled for 8:30 a.m. ET.
The conference call may be accessed by dialing (877) 845-1016 from the U.S. and Canada, or (708) 290-1155 from international locations. The conference call will also be available via the Internet at http://www.bg-medicine.com
A replay of the call will be available approximately one hour following the end of the call through August 12, 2012. The replay may be accessed by dialing (855) 859-2056 within the U.S. and Canada or (404) 537-3406 from international locations, conference ID # 16463217. The call will be available via webcast from the Investor Relations section of the Company's website at http://www.bg-medicine.com. To listen to the call via the Internet it is recommended that interested parties go to the website prior to the start time to register and install any necessary audio software.
About BG Medicine.
BG Medicine, Inc. (BGMD) is a life sciences company focused on the discovery, development and commercialization of novel, biomarker-based cardiovascular diagnostics to address significant unmet medical needs, improve patient outcomes and contain healthcare costs. The Company's first commercialized product, the BGM Galectin-3TM test for use in patients with heart failure, is available in the United States and Europe. BG Medicine is also developing CardioSCORE, a blood test designed to identify individuals at high risk for near-term major cardiovascular events, such as heart attack and stroke. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit http://www.bg-medicine.com and http://www.galectin-3.com.
The BG Medicine Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10352
SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: Certain statements made in this news release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "estimate," "anticipate" or other comparable terms. Forward-looking statements in this news release may address the following subjects among others: statements regarding the sufficiency of our capital resources, expected operating losses, expected license fee revenues, expected research and development expenses, expected general and administrative expenses and our expectations concerning our business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our recently filed S-1. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
Original post:
PHILADELPHIA A physician from the Perelman School of Medicine at the University of Pennsylvania has received the highest honor bestowed by the United States Government on science and engineering professionals in the early stages of their independent research careers. Peter Reese, MD, MSCE, assistant professor of Medicine and Epidemiology, received the Presidential Early Career Award for Scientists and Engineers for "innovative work on ethical approaches to expanding access to organ transplantation."
"I feel very grateful to receive this award. I owe a great deal to my mentors and collaborators at Penn for their support," said Dr. Reese. "I hope that the award will direct attention to the pressing need to increase organ donation and reduce waiting times for transplants."
Dr. Reese, who takes care of kidney transplant recipients and living kidney donors, received the PECASE award for his efforts to develop effective strategies to increase access to kidney and liver transplantation. He uses tools from epidemiology, biostatistics, health services research and medical ethics to describe disparities in transplantation and methods to overcome them. Through policy development work with the United Network for Organ Sharing (UNOS), his work helps to translate clinical research into effective national policy.
Dr. Reese's research was among the first to examine the practice and ethical implications of accepting live kidney donors with risk factors for kidney disease. He has written specifically about barriers to live donor transplantation, the use of kidneys from deceased donors at increased risk of HIV and other blood-borne viral infection, and the implications of proposed organ allocation systems for the elderly.
Dr. Reese's research efforts have been supported by the National Institutes of Health, the American Society of Transplantation, a T. Franklin Williams Award in geriatric research (co-sponsored by the Association of Specialty Professors and the American Society of Nephrology), and the Leonard Davis Institute.
For more information on the award, please see the press release from The White House.
###
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.
The Perelman School of Medicine is currently ranked #2 in U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $479.3 million awarded in the 2011 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; and Pennsylvania Hospital the nation's first hospital, founded in 1751. Penn Medicine also includes additional patient care facilities and services throughout the Philadelphia region.
Continued here:
Presidential Early Career Award for Scientists and Engineers Goes to Penn Medicine Researcher
A VETERINARY medicine supplier, Ceva Animal Health (formerly Nature Vet), was convicted last week on two counts under Australias agvet chemical laws for supplying veterinary antibiotics contrary to their permit conditions.
Under permit, Ceva was allowed to sell a combination of two antibioticsrifampicin and erythromycinunder very strict conditions to minimise the risk of antibiotic resistance developing. Both these antibiotics are important in human as well as animal medicine, with rifampicin being regarded as high importance in treating bacterial infections that are resistant to other antibiotics.
The APVMA uncovered the permit breaches through a compliance audit, following some irregularities identified through routine internal screening, said APVMAs Compliance Manager, Dr Jan Klaver.
Following Cevas guilty plea in the NSW Local Court, the court found the offences proven.
Ceva was convicted and fined $5000 for supplying the antibiotics contrary to requirements of Section 78 (1) of the Agricultural and Veterinary Chemicals Code Act 1994.
The company was also convicted and fined a further $3000 for wrongfully supplying these antibiotics beyond their use-by date. Costs were also awarded to the APVMA.
The APVMA is actively monitoring compliance of agvet chemicals and their supply with relevant manufacturing, registration and permit conditions, Dr Klaver said.
We make no apologies for taking strong action against companies who take chances with these products and even more so when we are dealing with products that are so important to human medicine as well.
The combination of erythromycin and rifampicin is a treatment of choice for Rhodococcus equi infectionan important cause of pneumonia in foalswhich may become established as an endemic disease at breeding facilities.
Immuno-compromised people, such as transplant patients or those with HIV-AIDS may also be at risk of contracting R. equi infections.
Go here to see the original:
This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.
Read the original:
PHILADELPHIA David A. Asch, MD, MBA, executive director of the Penn Medicine Center for Innovation and the Robert D. Eilers Professor of Health Care Management and Economics in the Perelman School of Medicine and the Wharton School at the University of Pennsylvania, has been appointed to serve as a member of the Institute of Medicine's new Committee on Governance and Financing of Graduate Medical Education.
The committee will be tasked with assessing the current regulation, financing, content, governance, and organization of U.S. graduate medical education (GME) and making recommendations for how to modify the system to "produce a physician workforce for a 21st century U.S. health care system that provides high quality preventive, acute, and chronic care, and meets the needs of an aging and more diverse population."
Among areas the committee will review, for example: the numbers of residency training slots in different specialty areas; the balance of primary care providers, specialists, and subspecialists; training sites; financing options; and the accreditation process for institutions that provide this training to new physicians. They will also examine relationships among safety net medical providers, community health/teaching health centers, and academic centers.
###
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.
The Perelman School of Medicine is currently ranked #2 in U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $479.3 million awarded in the 2011 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; and Pennsylvania Hospital the nation's first hospital, founded in 1751. Penn Medicine also includes additional patient care facilities and services throughout the Philadelphia region.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2011, Penn Medicine provided $854 million to benefit our community.
Read the rest here:
Penn Medicine Health Economist Named to IOM Committee on Graduate Medical Education Financing
DUBLIN--(BUSINESS WIRE)--
Research and Markets (http://www.researchandmarkets.com/research/z2m4zm/research_report_on) has announced the addition of the "Research Report on Chinese Medicine Intermediate Industry, 2012" report to their offering.
Medicine intermediates are the substances made from the raw material then used for finished products in the process of drug synthesis.
In China, the production of medicine intermediates doesn't require pharmaceutical production license. Common chemical plants can produce them, which can be applied in drug synthesis once qualified to certain levels. Medicine intermediates instead of drugs are the raw materials of drug synthesis.
Pharmaceutical industry largely demands special chemicals which was formerly produced by pharmaceutical industry itself, and partly shifted to chemical enterprises following the social division and the improvement of production technology. Medicine intermediates are categorized as fine chemical products, the production of which currently becomes a major emerging industry of international chemical industry.
At present, China needs more than 2,000 varieties of raw materials and medicine intermediates assorted with chemicals every year, the demand volume of which reaches over 2 million tons. With the development of over 30 years, China's chemical raw materials and intermediates needed in pharmaceutical production can basically be produced domestically and only a small part needs to be imported. In 2011, the output of China's medicine intermediates was nearly 3 million tons, the market scale of which surmounted CNY 300 billion.
The export of medicine intermediates is not under various restrictions compared with that of pharmaceuticals; pharmaceutical corporations in developed countries choose to import a large number of medicine intermediates from developing countries in consideration of production cost saving and environmental protection; meanwhile, the particularity of medicine intermediate industry enables China to enjoy an outstanding advantage globally in the industry, which all brings great opportunities to China's medicine intermediate enterprises.
Since China enjoys abundant resources and relatively low prices of raw materials, medicine intermediates are exported in a great number. In 2011, the net export of China's medicine intermediates surmounted 1 million tons. China, the largest export country of APIs(active pharmaceutical ingredients) and medicine intermediates, occupies a significant position in the global market.
It is predicted that China's medicine intermediate industry will remain a rapid development in the coming years.
More following information can be acquired through this report:
Continued here:
Research and Markets: Research Report on Chinese Medicine Intermediate Industry, 2012
SEOUL, SOUTH KOREA--(Marketwire -08/01/12)- The 16th International Congress of Oriental Medicine will be held on Sep 14th (Fri) - 16th (Sun), 2012 at COEX in Seoul co-hosted by organizing committee of the World Traditional Medicine Expo 2013 and the International Society of Oriental Medicine (ISOM) and organized by the Association of Korean Medicine (AKOM).
The congress on "The Future of Medicine, Traditional Medicine" will review the value of traditional medicine and find the right place of it in global health cooperated with WHO and Ministry of Health and Welfare of Korea.
The World's Best Congress on Traditional Medicine
The International Congress of Oriental Medicine (ICOM) is the oldest international congress in traditional medicine. Specifically, the 16th ICOM will serve as a pre-Expo of the World Traditional Medicine Expo in Sancheong, Korea 2013 to celebrate the 400th anniversary of the publication of Donguibogam which was listed on UNESCO's Memory of the World in 2009. The 16th ICOM will be the largest in its history with over 16,000 participants from more than 50 countries.
The congress will have presentations with 19 different topics, poster sessions, 11 workshops and government forum. In addition, the congress will build a global network for exchange and cooperation for development of traditional medicine. After the congress, participants will travel to Donguibogam village in Sancheong, the venue of the World Traditional Medicine Expo 2013 and field trip to hospital and pharmaceutical company for learning the progress of Korean medicine.
The venue of exchange for present and future of Korean Medicine (KM) industry
Korea, which hosted ICOM 7 times until this year, is putting forth the utmost effort to nurture Korean Medicine ('KM') and is also a leading country to standardize and scientifically develop traditional medicine.
The Korean Medicine Exhibition will be held during the congress in an effort to promote developed KM and traditional medicine. This exhibition will offer a venue of various experiences and exchanges to show the vision of future traditional medicine along with the product marketing.
An executive member of the ICOM said, "I am confident that this congress will offer an opportunity to reevaluate the value of traditional medicine which attracts global interest and demand. By sharing the latest study and research achievements related to the standardization and evidence-based medicine of traditional medicine, it could let the world know the excellent KM and traditional medicine."
To learn more about the 16th ICOM, visit http://www.icom2012.org/ Any enquiries, please contact the 16th ICOM Secretariat (+82 2-2657-5092, 5097 akom@icom2012.org).
Read more:
Korea Hosts the 16th International Congress of Oriental Medicine
There has been a huge increase in trials concerning food and medicine safety, but this indicates, at least in part, a more focused approach by legal authorities, a top legal official said.
The rest is here:
Public release date: 1-Aug-2012 [ | E-mail | Share ]
Contact: Christine A. Somosi 216-368-6287 Case Western Reserve University
Researchers at Case Western Reserve University School of Medicine have discovered a mutant form of the gene, Chk1, that when expressed in cancer cells, permanently stopped their proliferation and caused cell death without the addition of any chemotherapeutic drugs. This study illustrates an unprecedented finding, that artificially activating Chk1 alone is sufficient to kill cancer cells.
"We have identified a new direction for cancer therapy and the new direction is leading us to a reduction in toxicity in cancer therapy, compared with chemotherapy or radiation therapy," said Dr. Zhang, assistant professor, Department of Pharmacology at the School of Medicine, and member of the university's Case Comprehensive Cancer Center. "With this discovery, scientists could stop the proliferation of cancer cells, allowing physicians time to fix cells and genetic errors."
While studying the basic mechanisms for genome integrity, Dr. Zhang's team unexpectedly discovered an active mutant form of human Chk1, which is also a non-natural form of this gene. This mutation changed the protein conformation of Chk1 from the inactive form into an active form. Remarkably, the research team discovered that when expressed in cancer cells, this active mutant form of Chk1 permanently stopped cancer cell proliferation and caused cell death in petri dishes even without the addition of any chemotherapeutic drugs.
The biggest advantage of this potential strategy is that no toxic chemotherapeutic drug is needed to achieve the same cancer killing effect used with a combination of Chk1 inhibitors and chemotherapeutic drugs.
Cells respond to DNA damage by activating networks of signaling pathways, termed cell cycle checkpoints. Central to these genome pathways is the protein kinase, called Chk1. Chk1 facilitates cell survival, including cancer cells, under stressful conditions, such as those induced by chemotherapeutic agents, by placing a temporary stop on the cell cycle progression and coordinating repair programs to fix the DNA errors.
It has long been suggested that combining Chk1 inhibition with chemotherapy or radiotherapy should significantly enhance the anticancer effect of these therapies. This idea has serves as the basis for multiple pharmaceutical companies searching for potential Chk1 inhibitors that can effectively combine with chemotherapy in cancer therapy. To date, no Chk1 inhibitor has passed the clinical trial stage III . This led Dr. Zhang's team to look for alternative strategies for targeting Chk1 in cancer therapy.
Future research by Dr. Zhang and his team will consider two possible approaches to artificially activating Chk1 in cancer cells. One possibility is to use the gene therapy concept to deliver the active mutant form of Chk1 that the team discovered, into cancer cells. The other is to search for small molecules that can induce the same conformational change of Chk1, so that they can be delivered into cancer cells to activate Chk1 molecules. The consequence of either would be permanent cell proliferation inhibition and cancer.
###
See the rest here:
CWRU School of Medicine researchers discover gene that permanently stops cancer cell proliferation
Dr. Debra Schwinn will become dean of the Carver College of Medicine starting Nov. 1. Photo by Joshua Bessex.
The UW School of Medicine took a hit to its faculty ranks last week, when Debra Schwinn, the chair of the UWs department of anesthesiology and pain medicine, was appointed as the next dean of the University of Iowas Carver College of Medicine.
Schwinn, who also serves as an adjunct professor of pharmacology and genome sciences, came to the UW in 2007 after serving on the faculty of the Duke University Medical Center. She said the collaborative research and the environment at the UW were key to her decision to come.
The department was already strong, and I saw an opportunity to help it grow to be a model anesthesiology department in the U.S., outstanding in research as well as teaching and clinical care, said Schwinn.
Schwinn, who holds one Australian and four U.S. patents, is a nationally known investigator in molecular pharmacology and an elected member of the Institute of Medicine of the National Academies of Science.
Though leaving the UW after just five years, Schwinn said she is proud of the strides her programs have made. Under her watch, the department of anesthesiology and pain medicine established an interdisciplinary Mitochondria and Metabolism Center at UW Medicines South Lake Union campus, giving the school national prominence in mitochondrial biology. In addition, the schools chronic-pain program has become a world leader.
Our chronic-pain program, which had strong historical roots, has been transformed into an international leading program in outcomes-based clinical care as the vision of several key leaders who were recruited to UW from across the U.S. and Europe, said Schwinn. We have partnered with foundations and key visionary individuals who have donated funds to develop and enhance this center.
University of Iowa officials said Schwinn was a great pick for their open position.
Dr. Schwinn has an unmatched breadth and depth in her understanding of the future challenges and opportunities in academic medicine, said Donna Hammond, acting dean at the Carver College of Medicine. She is an extremely accomplished physician scientist, a committed educator and advocate of interprofessional education, and has a record of strong visionary leadership.
While Schwinn is excited to expand her role at Iowa, leaving the UW is bittersweet.
Originally posted here:
UW medicine chair appointed dean of Iowa College of Medicine
WASHINGTON, July 31, 2012 /PRNewswire-USNewswire/ -- The American College of Emergency Physicians (ACEP) and the Society for Academic Emergency Medicine (SAEM) today lauded the announcement by the National Institutes of Health (NIH) about the creation of a new Office of Emergency Care Research (OECR) as a gift to emergency patients everywhere. The NIH is the largest federal agency dedicated to ...
See the article here:
Medical schools throughout history have taught future doctors that medicine is both science and art, but the push to implement more rigorous scientific approach to medical care has diminished and marginalized the art of medicine in the last few decades.
The push to apply research-based data and evidence-based medicine has created a new culture where governments and policymakers are trying to force doctors to practice so called cook-book medicine.
It is a concept where people are treated, not as unique individual humans, but as a category of diagnosis for which they have a set of treatments recommended by experts. If you deviate from the standard recommendations, you may be penalized for not following the standard of care.
Proponents of this standardization of care have their merits; it is better for the population as a whole. More people with heart attacks are saved now than before, at least in part, because of the implementation of evidence-based medicine.
The opponents of this cook-book approach to medicine have become more vocal in the last few years and different concepts and terms have been defined to try to bring back the art of medicine back at the patients bedside.
One such concept called narrative medicine is gaining ground in some academic institutions. Narrative medicine encourages doctors to put the focus back on the story of illness. It encourages health care providers to listen to the unique human story of the patient and understand their unique situation before jumping to categorize the patient into a diagnostic algorithm that mechanically forces a common set of diagnostic tests and treatments to all patients in the category.
What is the best treatment for the masses may not be the best option for an individual patient. In my opinion, a fine balance between the evidence-based approach and subjective, individualized, narrative approach is needed to preserve the best interest of all patients.
When you are sick, the care you receive should be based on your unique situation, not what worked for people with similar diagnosis in a research study. The research findings should be used as a guideline to tailor a unique approach to your treatment based on your unique circumstances.
Ignoring the research findings would be a mistake but so would be using the one-size-fits-all approach to individual patients.
The narrative and subjective approach to medicine is especially important to patients who do not easily fit into a typical pattern of an illness. To get to the bottom of the cause of the suffering of that particular patient, we must first stop thinking about the standard set of diagnoses. If we dont, we will be trying to categorize the patient instead of trying to find the right diagnosis.
Here is the original post:
~"The Medicine Abuse Project" Will Prevent Half a Million Teens from Abusing Medicine in Five Years~NEW YORK, July 31, 2012 /PRNewswire-USNewswire/ -- The Partnership at Drugfree. ...
Read the rest here:
The Partnership at Drugfree.org Announces New Partners in National Medicine Abuse Action Campaign
BOCA RATON, FL--(Marketwire -07/31/12)- Modernizing Medicine, the creator of the Electronic Medical Assistant (EMA), a cloud-based specialty-specific EMR application, announced today that it is now integrated in more than 550 healthcare practices across the country, solidifying it as a strong contender in the EMR space.
In 2010, serial entrepreneur Dan Cane and dermatologist Michael Sherling co-founded Modernizing Medicine. Together the pair developed the company's flagship product, EMA. The speciality-specific EMR adapts to each healthcare providers' unique style of practice, and integrates seamlessly into the practice's workflow. EMA is available as a native iPad application and from any web-enabled Mac or PC. EMA's touch-based system virtually eliminates the need for a keyboard and saves valuable time by scribing notes, electronically prescribing, and automating lab requisition forms and results, and so much more.
In less than 18 months of sales, Modernizing Medicine has captured over 10% of the dermatology market in the United States. The company has grown to 75 employees and has secured a number of prestigious awards, including the number one spot in the South Florida Business Journal's Fastest Growing Companies 'Fast 50' list. EMA has achieved certification as a Complete EHR by the Certification Commission for Health Information Technology (CCHIT) and has earned Surescripts certification for prescription routing. Today, Modernizing Medicine provides specialty-specific offerings for the dermatology, ophthalmology and optometry markets.
Modernizing Medicine has recently added numerous specialty-specific healthcare practices to its customer roster including the Dermatology and Skin Cancer Center in Leawood, Kansas. The Dermatology and Skin Cancer Center is the largest dermatologic group in the Midwest and is recognized as one of the top treatment centers in the country. The practices' leaders chose EMA as its EMR over a number of other competitors.
"Before selecting Modernizing Medicine's EMA, we researched numerous other EMR systems. We choose EMA because we felt that Modernizing Medicine has truly developed an exceptional program that we feel is best suited for a dermatology and dermatologic surgery practice," said Dr. Glenn Goldstein, Director of the Dermatology and Skin Cancer Center. "EMA is incredibly well thought out and user-friendly. Modernizing Medicine has been with us from sale to implementation and we are truly impressed with all of their support."
"The Dermatology and Skin Cancer Center is the ideal customer for EMA. With a number of physicians and office staff, EMA makes it easy for all of the practices' authorized staff to access patient files on the fly and draft up a diagnosis or prescription quickly and efficiently in a collaborative manner," said James Brooks, Executive Vice President of Sales and Marketing for Modernizing Medicine. "We are excited to be supporting such a prestigious and complex group and look forward to supporting them as they continue to grow."
Modernizing Medicine plans to launch EMA for the plastics industry in late 2012 and for the orthopedic industry in early 2013.
About Modernizing MedicineModernizing Medicine is delivering the next generation of electronic medical records (EMR) technology for the healthcare industry. Our product, Electronic Medical Assistant (EMA), is a cloud-based specialty-specific EMR with a tremendous amount of medical content already built-in that saves physicians time. Available as a native iPad application or from any web-enabled Mac or PC, EMA adapts to each provider's unique style of practice and is designed to interface with over 400 different practice management systems. Today, Modernizing Medicine provides specialty-specific offerings for the dermatology, ophthalmology, and optometry markets, and to more than 500 practices across the country.
Original post: